SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Liquid biopsy and health-related quality of life in cancers: a systematic review.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Artificial intelligence-powered liquid biopsy in cancer: a paradigm shift in cancer detection and personalized care.Cancer cell international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy, using circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), is gaining ground as a noninvasive strategy in cancer care. Beyond its diagnostic and monitoring roles, its potential to impact health-related quality of life (HRQoL) is increasingly recognized. This review explores how liquid biopsy may influence HRQoL outcomes across various cancer types. A comprehensive literature search identified four studies that collectively included 2541 patients. The findings suggest a favorable impact on both emotional and functional well-being. In the BESPOKE CRC study, ctDNA testing reduced recurrence-related anxiety in 62% of patients, particularly in those testing negative (p < 0.0001). COMET linked elevated CTCs to emotional decline post-chemotherapy (p = 0.0137). LIQUID IMPACT found that 96% of patients had stable or improved symptoms, with nearly half maintaining or improving daily functioning. Corke et al. (2002) observed better quality of life with targeted therapy based on liquid biopsy, alongside a strong patient preference for the test (p = 0.04). Overall, liquid biopsy shows promise in enhancing HRQoL by supporting personalized care and reducing emotional burden. However, more research is needed to validate these outcomes and explore long-term patient-centered benefits.
Indexed as
Identifiers
41254449What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.